RNA
Avidity Biosciences, Inc. · Healthcare · Market cap $140.1M
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.6M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Latest filing
Sep 22, 2026
Flanagan W. Michael
Avidity Biosciences, Inc. (RNA) has 38 SEC Form 4 filings (56 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Sep 22, 2026.
Inside the rolling window, 9 insiders at Avidity Biosciences, Inc. reported no open-market purchases and 16 open-market sales totaling $5.6M. The most active filer is Chief Human Resources Officer McCarthy Teresa with 3 filings. The most recent open-market filing is a sale of 6,534 shares by Chief Scientific Officer Flanagan W. Michael, dated Jan 21, 2026, worth $473K.
- Industry:Biotechnology
- CEO:Kathleen Gallagher
- Employees:511
- HQ:San Diego, CA, US
- IPO:2026-02-27
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 6,534 | $473K | Jan 23 | -44.5% | SEC ↗ | |
| Chief Financial Officer | Sale | 4,542 | $329K | Jan 23 | -44.5% | SEC ↗ | |
| Chief Human Resources Officer | Sale | 2,929 | $212K | Jan 23 | -44.5% | SEC ↗ | |
| Chief Medical Officer | Sale | 4,895 | $355K | Jan 23 | -44.5% | SEC ↗ | |
| President and CEO | Sale | 14,387 | $1.0M | Jan 23 | -44.5% | SEC ↗ | |
LEVIN ARTHUR AFirst filing | Director | Sale | 1,758 | $127K | Jan 23 | — | SEC ↗ |
MacLean Michael FFirst filing | Chief Financial Officer | Sale | 1,974 | $143K | Jan 9 | — | SEC ↗ |
| Chief Human Resources Officer | Sale | 1,965 | $142K | Jan 9 | — | SEC ↗ | |
| Chief Medical Officer | Sale | 2,373 | $171K | Jan 9 | — | SEC ↗ | |
Flanagan W. MichaelFirst filing | Chief Scientific Officer | Sale | 2,373 | $171K | Jan 9 | — | SEC ↗ |
Boyce SarahFirst filing | President and CEO | Sale | 8,576 | $619K | Jan 9 | — | SEC ↗ |
Moriarty John BFirst filing | Chief Legal Officer | Sale | 2,374 | $171K | Jan 9 | — | SEC ↗ |
Calderaro Charles IIIFirst filing | Chief Technical Officer | Sale | 3,727 | $269K | Jan 9 | — | SEC ↗ |
Hughes Steven GeorgeFirst filing | Chief Medical Officer | Sale | 2,209 | $105K | Oct 24 | — | SEC ↗ |
McCarthy TeresaFirst filing | Chief Human Resources Officer | Sale | 20,000 | $1.0M | Oct 17 | — | SEC ↗ |
Mosbrooker EricFirst filing | Chief Commercial Officer | Sale | 6,562 | $298K | Oct 7 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does RNA have?
Avidity Biosciences, Inc. (RNA) has 38 SEC Form 4 filings (56 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Sep 22, 2026.
When was the most recent SEC Form 4 filing for RNA?
The most recent Form 4 filing for RNA on Tracefour is dated Sep 22, 2026.
Who is the most active insider at RNA?
The most active SEC Form 4 filer at RNA in the rolling window is Chief Human Resources Officer McCarthy Teresa, with 3 filings.
What is the total insider buy and sell value at RNA in the current window?
Inside the rolling window, insiders at RNA bought $0 and sold $5.6M based on SEC Form 4 filings.
Can I get alerts for RNA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Avidity Biosciences, Inc. (RNA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Avidity Biosciences, Inc. is in the Healthcare sector.